Fulgent Genetics (NASDAQ:FLGT) Reaches New 52-Week Low – Should You Sell?

Fulgent Genetics, Inc. (NASDAQ:FLGT)’s stock price hit a new 52-week low on Thursday . The company traded as low as $18.86 and last traded at $18.88, with a volume of 55579 shares traded. The stock had previously closed at $19.18.

Fulgent Genetics Trading Up 1.4 %

The stock has a market cap of $581.12 million, a price-to-earnings ratio of -3.49 and a beta of 1.50. The stock’s 50 day moving average is $21.44 and its two-hundred day moving average is $21.41.

Fulgent Genetics (NASDAQ:FLGT) last released its earnings results on Friday, August 2nd. The company reported $0.15 EPS for the quarter, topping the consensus estimate of ($0.30) by $0.45. Fulgent Genetics had a negative net margin of 56.22% and a negative return on equity of 2.75%. The company had revenue of $71.03 million during the quarter, compared to analysts’ expectations of $69.07 million. During the same quarter last year, the business earned ($0.33) EPS. The business’s revenue was up 4.7% on a year-over-year basis. On average, sell-side analysts predict that Fulgent Genetics, Inc. will post -1.46 EPS for the current year.

Insider Transactions at Fulgent Genetics

In other news, CEO Ming Hsieh sold 2,313 shares of the firm’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $22.83, for a total value of $52,805.79. Following the completion of the sale, the chief executive officer now owns 707,275 shares in the company, valued at approximately $16,147,088.25. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders sold 4,324 shares of company stock worth $98,717. Company insiders own 31.76% of the company’s stock.

Institutional Trading of Fulgent Genetics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Asset Dedication LLC acquired a new stake in shares of Fulgent Genetics in the second quarter valued at about $33,000. nVerses Capital LLC acquired a new stake in shares of Fulgent Genetics in the second quarter valued at about $43,000. Signaturefd LLC lifted its stake in shares of Fulgent Genetics by 103.6% in the second quarter. Signaturefd LLC now owns 2,225 shares of the company’s stock valued at $44,000 after purchasing an additional 1,132 shares during the period. Canada Pension Plan Investment Board acquired a new stake in shares of Fulgent Genetics in the second quarter valued at about $63,000. Finally, State Board of Administration of Florida Retirement System acquired a new stake in shares of Fulgent Genetics in the first quarter valued at about $178,000. Institutional investors and hedge funds own 48.06% of the company’s stock.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.